ADZYNMA

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
ADZYNMA
Generic name
APADAMTASE ALFA
Manufacturer
TAKEDA PHARMACEUTICALS AMERICA, INC.
Product type
HUMAN PRESCRIPTION DRUG
SPL set ID
22728e96-efa0-46c1-bdd1-ad89a796d5e3
SPL ID
1054faf4-b766-485d-bb45-1651d3fa8cb9
Version
10
Effective date
2026-10-30
Source export date
2026-11-13
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:31:52

Boxed warning cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Boxed warning sections page 1 of 1 · 1 matching rows.

boxed warning

WARNING: NEUTRALIZING ANTIBODIES TO ADAMTS13 Neutralizing antibodies to ADAMTS13 with serious outcomes, including death, have been reported in patients treated with ADZYNMA. Neutralizing antibodies may result in decreased or lack of response to recombinant or plasma-derived ADAMTS13 [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) ] . Monitor all patients closely for ADAMTS13 activity and development of ADAMTS13 neutralizing antibodies [see Warnings and Precautions (5.1) ] . WARNING: NEUTRALIZING ANTIBODIES TO ADAMTS13 See full prescribing information for complete boxed warning. Neutralizing antibodies to ADAMTS13 with serious outcomes, including death, have been reported in patients treated with ADZYNMA. Neutralizing antibodies may result in decreased or lack of response to recombinant or plasma-derived ADAMTS13 ( 5.1 , 6.2 ). Monitor all patients closely for ADAMTS13 activity and development of ADAMTS13 neutralizing antibodies ( 5.1 ).

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Neutralizing antibodies to ADAMTS13 with serious outcomes including death have been reported in patients with cTTP following administration of ADZYNMA. Monitor all patients, including those who were previously exposed or naïve to plasma-based products, by assessing ADAMTS13 activity and ADAMTS13 neutralizing antibodies prior to initiation of ADZYNMA and periodically during the course of treatment. ( 5.1 , 6.2 ) Hypersensitivity reactions may occur. Discontinue ADZYNMA if hypersensitivity symptoms occur and administer appropriate emergency treatment. ( 5.2 ) 5.1 Neutralizing Antibodies Neutralizing antibodies to ADAMTS13 with serious outcomes including death have occurred following ADZYNMA administration [see Adverse Reactions (6.2) ] . Neutralizing antibodies may result in a decreased or lack of response to recombinant or plasma-derived ADAMTS13 which could lead to serious disease related outcomes. Neutralizing antibodies were not reported in the cTTP clinical trials. All subjects had been previously exposed to ADAMTS13 through plasma-based products. There are no data on immunogenicity with ADZYNMA in previously untreated patients (subjects naïve to plasma-based products) [see Clinical Pharmacology (12.6) ] . Monitor all patients, including those who were previously exposed or naïve to plasma-based products, by assessing ADAMTS13 activity and ADAMTS13 neutralizing antibodies prior to initiation of ADZYNMA and periodically during the course of treatment. If expected ADAMTS13 activity levels are not attained or if acute TTP exacerbation occurs despite appropriate dose, perform an assay that measures ADAMTS13 neutralizing antibody concentrations. Laboratory tests for monitoring neutralizing antibody levels are not capable of distinguishing between inhibitors directed against ADZYNMA, the patient’s endogenous ADAMTS13, or ADAMTS13 from other plasma sources. 5.2 Hypersensitivity Reactions Hypersensitivity reactions including anaphylaxis may occur with ADZYNMA. Monitor patients for sign and symptoms of hypersensitivity reactions which may include tachycardia, tightness of the chest, wheezing and/or acute respiratory distress, hypotension, generalized urticaria, pruritus, rhinoconjunctivitis, angioedema, lethargy, nausea, vomiting, paresthesia, and restlessness. If signs and symptoms of severe hypersensitivity reactions occur, immediately discontinue administration of ADZYNMA and provide appropriate supportive care.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS Most common adverse reactions (incidence >5%) are headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness, and vomiting. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety profile of ADZYNMA was evaluated in one, prospective, randomized, active-controlled, open-label, multicenter, two-period crossover study (Study 1) that treated 48 patients who had been previously exposed to ADAMTS13 through plasma-based products. Patients received ADZYNMA at the dose of 40 IU/kg/dose. The adverse drug reactions (ADR) are listed in Table 2 . Table 2: Adverse Reactions Reported in >5% of Patients Treated with ADZYNMA Adverse Reaction ADZYNMA (N= 48) n (%) Percentages by patient were calculated using the number of all subjects who had the listed adverse event. N = Total number of patients treated with ADZYNMA in Study 1. n = Number of patients who had at least one event in the category. Headache 15 (31.3) Diarrhea 8 (16.7) Migraine 7 (14.6) Abdominal pain 6 (12.5) Nausea 6 (12.5) Upper respiratory tract infection 6 (12.5) Dizziness 5 (10.4) Vomiting 5 (10.4) 6.2 Postmarketing Experience The following adverse reactions have been reported during the post-approval use of ADZYNMA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. Blood and lymphatic system: Neutralizing antibodies to ADAMTS13 with serious outcomes including death [see Warnings and Precautions (5.1) ] .

adverse reactions table

<table width="80%" ID="table2"> <caption>Table 2: Adverse Reactions Reported in &gt;5% of Patients Treated with ADZYNMA</caption> <col width="50%" align="left" valign="middle"/> <col width="50%" align="center" valign="middle"/> <thead> <tr> <th styleCode="Lrule Rrule" valign="top">Adverse Reaction</th> <th styleCode="Rrule">ADZYNMA (N= 48) n (%)<footnote>Percentages by patient were calculated using the number of all subjects who had the listed adverse event.</footnote> </th> </tr> </thead> <tfoot> <tr> <td colspan="2" align="left" valign="top">N = Total number of patients treated with ADZYNMA in Study 1. n = Number of patients who had at least one event in the category.</td> </tr> </tfoot> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Headache</td> <td styleCode="Rrule">15 (31.3)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Diarrhea</td> <td styleCode="Rrule">8 (16.7)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Migraine</td> <td styleCode="Rrule">7 (14.6)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Abdominal pain</td> <td styleCode="Rrule">6 (12.5)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Nausea</td> <td styleCode="Rrule">6 (12.5)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Upper respiratory tract infection</td> <td styleCode="Rrule">6 (12.5)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Dizziness</td> <td styleCode="Rrule">5 (10.4)</td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule">Vomiting</td> <td styleCode="Rrule">5 (10.4)</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.